Search
Oprelvekin
go.drugbank.com/drugs/DB00038ApprovedInvestigationalWithdrawnOprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long.
Synonyms: IL-11Phenmetrazine
go.drugbank.com/drugs/DB00830ApprovedIllicitA sympathomimetic drug used primarily as an appetite depressant. Its actions and mechanisms are similar to dextroamphetamine.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 2-phenyl-3-methylmorpholineEnoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. … It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.
Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-RingCladribine
go.drugbank.com/drugs/DB00242ApprovedInvestigational[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell … [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]
Categories: 2-Chloroadenosine, P-glycoprotein substratesSynonyms: (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purineFlosequinan
go.drugbank.com/drugs/DB13228ApprovedWithdrawnFlosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Categories: Vasodilators Used in Cardiac Diseases, Heterocyclic Compounds, 2-RingIpecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency … use to cause vomiting in poisoning.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIbuprofen Action Pathway
smpdb.ca/view/SMP0000086Drug actionInhibiting COX makes prostaglandin creation more sparse, thus resulting in less pain for the patient using ibuprofen. … Ibuprofen is typically ingested orally, although in the USA an intravenous version can be used. It inhibits cyclooxygenase (COX) non-selectively.
Enzymes: Prostaglandin E synthaseValaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalIt was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir. … Valaciclovir (valacyclovir), also known as _Valtrex_, is an antiviral drug that has been used to manage and treat various herpes infections for more than 2 decades.
Categories: Heterocyclic Compounds, 2-RingSynonyms: L-Valine, 2-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)ethyl ester, L-Valine ester with 9-((2-hydroxyethoxy)methyl)guanineCobicistat
go.drugbank.com/drugs/DB09065ApprovedInvestigationalMore specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 … Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered
Mixtures: PREZCOBIX® TABLETAS RECUBIERTAS, GENVOYA ® TABLETAS RECUBIERTASCategories: Antivirals used in combination for the treatment of HIV infections, P-glycoprotein inhibitorsPlerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigationalPlerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. … [A7117] Compared to placebo with G-CSF, the plerixafor and G-CSF mobilization regimen has a higher probability of achieving the optimal CD34+ cell target for tandem transplantation in fewer apheresis procedures
Products: MOZOBIL®, Enjeksiyonluk Çözelti, 1 ADET